《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2014年 > 9期

 芪药消渴胶囊逆转2型糖尿病慢性肾脏疾病微量白蛋白尿的研究

来自:中国糖尿病杂志  编辑:倪青 姜山 肖月星 冯兴中 李建民 朱章|点击数:|2014-09-24

 •糖尿病性肾脏疾病•

  【摘要】 目的 观察芪药消渴胶囊对糖尿病慢性肾脏疾病(CKD)微量白蛋白尿的影响。 方法 采用多中心、随机、双盲、安慰剂对照试验,共224例T2DM慢性肾脏疾病微量白蛋白尿患者纳入研究,其中试验(T)组116例,对照(PC)组108例,两组在接受常规治疗的基础上,T组加用芪药消渴胶囊,PC组加用安慰剂,治疗16周。比较两组治疗前后24 hUAER、肾功能、血糖、血脂等指标的变化。 结果 与治疗前相比,治疗后两组患者的24 hUAER、肾功能、血糖、血脂等指标均有所改善(P<0.05),T组与PC组相比差异有统计学意义(P<0.05)。 结论 芪药消渴胶囊能够逆转CKD微量白蛋白尿,保护肾功能,延缓CKD的进展。

  【关键词】 芪药消渴胶囊;糖尿病慢性肾脏疾病;尿微量白蛋白;中药

  【Abstract】 Objective To observe the influence of QiyaoXiaoke capsule on Microalbminurine in T2DM with chronic kidney disease (CKD). Methods The multicenter, randomized, double-blind and placebo control experiments were adopted in this study. 224 cases of patients with CKD were observed, which was divided into trial (T) group with 116 patients and placebo control (PC) group with 108 patients. Two groups were on the basis of routine treatment for 16 weeks, group T was added of QiyaoXiaoke capsule, group PC was added of placebo capsule. The aim was to compare blood glucose, blood lipid, renal function, 24 hUAER. Results After treatment, 24 hUAER, renal function, blood glucose and blood lipid are improved (P<0.05). In addition, the improvement in group T is superior to group PC. The difference between group T and PC has statistical significance (P<0.05). Conclusion QiyaoXiaoke capsule can reverse microalbuminuria in CKD, protect renal function, delay the progression of CKD.

  【Key words】 QiyaoXiaoke capsule; Chronic kidney disease (CKD); Microalbminurine; Traditional Chinese medicine

上一篇:血压与2型糖尿病患者尿白蛋白/肌酐比值关系的临床研究 下一篇:非老年男性糖尿病慢性肾脏疾病对骨代谢影响的初步报告